The effects of 5-fluorouracil and doxorubicin on expression of human immunodeficiency virus type 1 long terminal repeat. NLM AIDSLINE Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The effects of 5-fluorouracil and doxorubicin on expression of human immunodeficiency virus type 1 long terminal repeat.

Cancer Lett. 1996 Aug 2;105(2):217-23. Unique Identifier : AIDSLINE MED/96319712
Panozzo J; Akan E; Griffiths TD; Woloschak GE; Center for Mechanistic Biology and Biotechnology, Argonne; National Laboratory, IL 60439-4833, USA.

Abstract: Previous work by many groups has documented induction of the human immunodeficiency virus (HIV) long terminal repeat (LTR) following exposure of cells to ultraviolet light and other DNA damaging agents. Our experiments set out to determine the relative activation or repression of the HIV-LTR in response to two classes of chemotherapeutic agents: Doxorubicin is a DNA damage-inducing agent, and 5-fluorouracil has an antimetabolic mode of action. Using HeLa cells stably transfected with a construct in which HIV-LTR drives expression of the chloramphenicol acetyl transferase reporter gene, we demonstrated an up to ten-fold induction following doxorubicin treatment at 24 h post-treatment. This induction was repressed by treatment with salicylic acid, suggesting a role for prostaglandin/cyclo-oxygenase pathways and/or NF-kappa B in the inductive response. Induction by 5-fluorouracil, in contrast, was more modest (two-fold at most) though it was consistently elevated over controls.
Keywords: Antibiotics, Anthracycline/*PHARMACOLOGY Antimetabolites, Antineoplastic/*PHARMACOLOGY Dose-Response Relationship, Drug Doxorubicin/*PHARMACOLOGY Fluorouracil/*PHARMACOLOGY Gene Expression Regulation, Viral/*DRUG EFFECTS/RADIATION EFFECTS Genes, Reporter/DRUG EFFECTS/GENETICS/RADIATION EFFECTS Hela Cells Human HIV Long Terminal Repeat/*DRUG EFFECTS/RADIATION EFFECTS HIV-1/GENETICS Support, U.S. Gov't, Non-P.H.S. Transfection Ultraviolet Rays JOURNAL ARTICLEKWDantibiotics,anthracycline/KWDpharmacologyantimetabolites,antineoplastic/KWDpharmacologydose-responserelationship,drugdoxorubicin/KWDpharmacologyfluorouracil/KWDpharmacologygeneexpressionregulation,viral/KWDdrugeffects/radiationeffectsgenes,reporter/drugeffects/genetics/radiationeffectshelacellshumanhivlongterminalrepeat/KWDdrugeffects/radiationeffectshiv-1/geneticssupport,uKWDsKWDgov't,non-pKWDhKWDsKWDtransfectionultravioletraysjournalarticle
961130
M96B1847

Copyright © 1996 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .